Siegfried at 150

Abstract

The Swiss pharmaceutical services firm Siegfried recently announced the acquisition of DiNAMIQS, a maker of viral vectors for cell and gene therapy, and it plans to build a commercial-scale manufacturing facility at DiNAMIQS’s site in Schlieren, Switzerland, scheduled to open in 2025. Siegfried’s “mid double-digit million Swiss Francs” purchase of 95% of DiNAMIQS, as the deal is described in a press release, is modest compared with acquisitions in cell and gene therapy by larger services firms, such as Thermo Fisher Scientific and WuXi AppTec . But the biologics function adds a fundamentally new facet to Siegfried, which has grown rapidly over the past 15 years in its effort to provide drug industry customers with services for both active pharmaceutical ingredients (APIs), known as drug substance, and finished drugs, known as drug product. The deal also suggests a continuing transformation at the once-family-owned company, which announced the deal on the eve